Cargando…
Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
Advanced bladder cancer patients have limited therapeutic options resulting in a median overall survival (OS) between 12 and 15 months. Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL) has been used successfully in treating patients with metastatic melanoma, resulting in a medi...
Autores principales: | Poch, Michael, Hall, MacLean, Joerger, Autumn, Kodumudi, Krithika, Beatty, Matthew, Innamarato, Pasquale P., Bunch, Brittany L., Fishman, Mayer N., Zhang, Jingsong, Sexton, Wade J., Pow-Sang, Julio M., Gilbert, Scott M., Spiess, Philippe E., Dhillon, Jasreman, Kelley, Linda, Mullinax, John, Sarnaik, Amod A, Pilon-Thomas, Shari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140546/ https://www.ncbi.nlm.nih.gov/pubmed/30228944 http://dx.doi.org/10.1080/2162402X.2018.1476816 |
Ejemplares similares
-
The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications
por: Aydin, Ahmet Murat, et al.
Publicado: (2021) -
T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model
por: Liu, Hao, et al.
Publicado: (2018) -
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
por: Hall, MacLean, et al.
Publicado: (2016) -
Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors
por: Innamarato, Patrick, et al.
Publicado: (2021) -
Efficacy of intralesional injection with PV-10 in combination with co-inhibitory blockade in a murine model of melanoma
por: Pilon-Thomas, Shari, et al.
Publicado: (2014)